Cue Biopharma Q1 net loss $5.2M; appoints new CEO, $30M private placement, CUE-221 license

Cue Biopharma, Inc.

2026-Q1 EPS reported -$1.08 revenue$5,686,000

Net loss $5.2M ($1.08 EPS) vs $12.3M loss in Q1 2025; revenue $5.7M from Boehringer collaboration.
Appointed Shao-Lee Lin, M.D., Ph.D., as President, CEO and Board Director.
Completed $30M private placement (pre-funded and common warrants); received $7.5M milestone from Boehringer.
Exclusive license for CUE-221 (Phase 2 anti-IgE) from Ascendant Health; IND amendment for food allergy expected H2 2026.
Cash $16.4M at Mar 31, 2026; subsequent $30M private placement extends runway for clinical milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cue Biopharma, Inc. reported the quarter ended March 31, 2026 results: revenue $5.7 million, net income Net loss ... $5.2 million, EPS $(1.08) per common share – basic and diluted.

Period: the quarter ended March 31, 2026
Revenue: $5.7 million
Net income: Net loss ... $5.2 million
EPS: $(1.08) per common share – basic and diluted
Result: reported results

Exact text from the filing

to the FDA in the second half of 2026 • Phase 1 first-in-human study expected to be initiated by year-end 2026. First Quarter 2026 Financial Results First quarter revenue was $5.7 million compared to $0.4 million in the first quarter of 2025. The revenue earned during the three months ended March 31, 2026 was related to the Boehringer Ingelheim collaboration and

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cue Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-224101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.